|Bid||734.95 x 1400|
|Ask||738.09 x 800|
|Day's range||740.56 - 759.45|
|52-week range||556.35 - 818.60|
|Beta (5Y monthly)||0.87|
|PE ratio (TTM)||5.52|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Strength in Bio Rad's (BIO) key product lines across major geographic regions buoys optimism.
Investors are optimistic about Bio-Rad (BIO) on strength in its key product lines and raised 2021 guidance.
Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.